Max Crispin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2908510/publications.pdf

Version: 2024-02-01

166 papers	14,233 citations	25034 57 h-index	26613 107 g-index
201 all docs	201 docs citations	201 times ranked	15477 citing authors

#	Article	IF	Citations
1	Site-specific glycan analysis of the SARS-CoV-2 spike. Science, 2020, 369, 330-333.	12.6	1,277
2	Molecular Architecture of the SARS-CoV-2 Virus. Cell, 2020, 183, 730-738.e13.	28.9	793
3	A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield. Science, 2011, 334, 1097-1103.	12.6	644
4	Quantitative mass imaging of single biological macromolecules. Science, 2018, 360, 423-427.	12.6	453
5	Exploitation of glycosylation in enveloped virus pathobiology. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1480-1497.	2.4	383
6	Emerging Principles for the Therapeutic Exploitation of Glycosylation. Science, 2014, 343, 1235681.	12.6	381
7	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	28.9	379
8	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell, 2015, 163, 1702-1715.	28.9	341
9	Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. Journal of Clinical Investigation, 2013, 123, 2183-2192.	8.2	310
10	Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13800-13805.	7.1	309
11	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nature Communications, 2020, 11, 2688.	12.8	304
12	Glycoprotein Structural Genomics: Solving the Glycosylation Problem. Structure, 2007, 15, 267-273.	3.3	273
13	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Reports, 2016, 14, 2695-2706.	6.4	250
14	Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility. Journal of Molecular Biology, 2002, 319, 9-18.	4.2	246
15	SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax, 2020, 75, 1089-1094.	5.6	234
16	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science, 2019, 363, 649-654.	12.6	227
17	The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade. PLoS ONE, 2011, 6, e23521.	2.5	201
18	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell Reports, 2017, 20, 1805-1817.	6.4	171

#	Article	IF	Citations
19	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell, 2021, 184, 1188-1200.e19.	28.9	154
20	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine, 2017, 214, 2573-2590.	8.5	151
21	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature Communications, 2019, 10, 4272.	12.8	149
22	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2017, 2, 16199.	13.3	144
23	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Reports, 2015, 11, 1604-1613.	6.4	135
24	A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nature Genetics, 2021, 53, 205-214.	21.4	125
25	Molecular Mechanism of Lipopeptide Presentation by CD1a. Immunity, 2005, 22, 209-219.	14.3	122
26	An Endoglycosidase with Alternative Glycan Specificity Allows Broadened Glycoprotein Remodelling. Journal of the American Chemical Society, 2012, 134, 8030-8033.	13.7	122
27	Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell Reports, 2018, 24, 1958-1966.e5.	6.4	120
28	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, 2021, 7, 594-602.	11.3	118
29	Dissecting the Molecular Mechanism of IVIg Therapy: The Interaction between Serum IgG and DC-SIGN is Independent of Antibody Glycoform or Fc Domain. Journal of Molecular Biology, 2013, 425, 1253-1258.	4.2	116
30	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	12.8	116
31	Structure and Immune Recognition of the HIV Glycan Shield. Annual Review of Biophysics, 2018, 47, 499-523.	10.0	115
32	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nature Communications, 2015, 6, 7479.	12.8	113
33	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. Immunity, 2019, 51, 915-929.e7.	14.3	111
34	Crystal Structure and Carbohydrate Analysis of Nipah Virus Attachment Glycoprotein: a Template for Antiviral and Vaccine Design. Journal of Virology, 2008, 82, 11628-11636.	3.4	109
35	Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. Aids, 2014, 28, 2523-2530.	2.2	108
36	The Glycosylation of Human Serum IgD and IgE and the Accessibility of Identified Oligomannose Structures for Interaction with Mannan-Binding Lectin. Journal of Immunology, 2004, 173, 6831-6840.	0.8	100

#	Article	IF	Citations
37	Structural principles controlling HIV envelope glycosylation. Current Opinion in Structural Biology, 2017, 44, 125-133.	5.7	99
38	Structural analysis of glycoproteins: building N-linked glycans with<i>Coot</i>. Acta Crystallographica Section D: Structural Biology, 2018, 74, 256-263.	2.3	97
39	A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. Journal of Immunological Methods, 2015, 417, 34-44.	1.4	95
40	Structure of the Lassa virus glycan shield provides a model for immunological resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7320-7325.	7.1	95
41	Protein and Glycan Mimicry in HIV Vaccine Design. Journal of Molecular Biology, 2019, 431, 2223-2247.	4.2	91
42	Dimeric Architecture of the Hendra Virus Attachment Glycoprotein: Evidence for a Conserved Mode of Assembly. Journal of Virology, 2010, 84, 6208-6217.	3.4	90
43	Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. Journal of Virology, 2015, 89, 8932-8944.	3.4	88
44	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of Virology, 2015, 89, 12189-12210.	3.4	88
45	Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7154-7159.	7.1	87
46	Crystal structure of sialylated IgG Fc: Implications for the mechanism of intravenous immunoglobulin therapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3544-6.	7.1	84
47	Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell Reports, 2018, 23, 90-99.	6.4	80
48	Engineering Hydrophobic Proteinâ€“Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies. Journal of the American Chemical Society, 2013, 135, 9723-9732.	13.7	78
49	Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology, 2010, 20, 812-823.	2.5	77
50	Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. Journal of Virology, 2017, 91, .	3.4	77
51	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIVâ€1 envelope glycoprotein vaccine candidate. Biotechnology and Bioengineering, 2018, 115, 885-899.	3.3	75
52	HIV-1 vaccine design through minimizing envelope metastability. Science Advances, 2018, 4, eaau6769.	10.3	75
53	Sensitive Detection of SARS-CoV-2â€“Specific Antibodies in Dried Blood Spot Samples. Emerging Infectious Diseases, 2020, 26, 2970-2973.	4.3	74
54	Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Current Opinion in Virology, 2015, 11, 63-69.	5.4	73

#	Article	IF	Citations
55	Unusual Molecular Architecture of the Machupo Virus Attachment Glycoprotein. Journal of Virology, 2009, 83, 8259-8265.	3.4	71
56	Inhibition of Mammalian Glycan Biosynthesis Produces Non-self Antigens for a Broadly Neutralising, HIV-1 Specific Antibody. Journal of Molecular Biology, 2007, 372, 16-22.	4.2	68
57	Carbohydrate and Domain Architecture of an Immature Antibody Glycoform Exhibiting Enhanced Effector Functions. Journal of Molecular Biology, 2009, 387, 1061-1066.	4.2	67
58	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of Virology, 2019, 93, .	3.4	66
59	Ion Mobility Mass Spectrometry for Extracting Spectra <i>of N</i>-Glycans Directly from Incubation Mixtures Following Glycan Release: Application to Glycans from Engineered Glycoforms of Intact, Folded HIV gp120. Journal of the American Society for Mass Spectrometry, 2011, 22, 568-581.	2.8	65
60	Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis. Journal of the American Chemical Society, 2012, 134, 17554-17563.	13.7	65
61	Subtle Influence of ACE2 Glycan Processing on SARS-CoV-2 Recognition. Journal of Molecular Biology, 2021, 433, 166762.	4.2	64
62	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS Pathogens, 2019, 15, e1007920.	4.7	61
63	Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. BioDrugs, 2017, 31, 151-166.	4.6	58
64	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell Reports, 2017, 21, 222-235.	6.4	58
65	Identification of Lewis and Blood Group Carbohydrate Epitopes by Ion Mobility-Tandem-Mass Spectrometry Fingerprinting. Analytical Chemistry, 2017, 89, 2318-2325.	6.5	57
66	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of Virology, 2017, 91, .	3.4	57
67	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry, 2021, 60, 2153-2169.	2.5	54
68	Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor Interactions. Journal of Molecular Biology, 2012, 420, 1-7.	4.2	53
69	Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology, 2006, 16, 748-756.	2.5	52
70	MALDI-MS/MS with Traveling Wave Ion Mobility for the Structural Analysis of <i>N</i>-Linked Glycans. Journal of the American Society for Mass Spectrometry, 2012, 23, 1955-1966.	2.8	52
71	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS Pathogens, 2020, 16, e1008665.	4.7	52
72	Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. Nature Communications, 2018, 9, 1956.	12.8	50

#	Article	IF	Citations
73	Travelling wave ion mobility and negative ion fragmentation for the structural determination of <i>N</i>â€linked glycans. Electrophoresis, 2013, 34, 2368-2378.	2.4	49
74	Cryo-EM Structures of Eastern Equine Encephalitis Virus Reveal Mechanisms of Virus Disassembly and Antibody Neutralization. Cell Reports, 2018, 25, 3136-3147.e5.	6.4	49
75	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. Cell Reports, 2018, 24, 3324-3338.e5.	6.4	49
76	Building meaningful models of glycoproteins. Nature Structural and Molecular Biology, 2007, 14, 354-354.	8.2	48
77	Differentiation between isomeric triantennary <i>N</i>â€linked glycans by negative ion tandem mass spectrometry and confirmation of glycans containing galactose attached to the bisecting (<i>Î²</i>1â€4â€GlcNAc) residue in <i>N</i>â€glycans from IgG. Rapid Communications in Mass Spectrometry, 2008, 22, 1047-1052.	1.5	48
78	Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Letters, 2004, 566, 270-274.	2.8	47
79	Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1655-1668.	2.4	47
80	Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. Structure, 2020, 28, 897-909.e6.	3.3	46
81	HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. Journal of Virology, 2016, 90, 11132-11144.	3.4	43
82	Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. Retrovirology, 2016, 13, 8.	2.0	40
83	Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients. Journal of Immunological Methods, 2021, 494, 113046.	1.4	40
84	The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans. Structure, 2017, 25, 773-782.e5.	3.3	39
85	Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage. Frontiers in Immunology, 2018, 9, 1631.	4.8	37
86	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell Reports, 2021, 35, 108933.	6.4	37
87	A Human Embryonic Kidney 293T Cell Line Mutated at the Golgi Î±-Mannosidase II Locus. Journal of Biological Chemistry, 2009, 284, 21684-21695.	3.4	35
88	Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. Journal of Virology, 2015, 89, 6952-6959.	3.4	35
89	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. Cell Reports, 2019, 27, 2426-2441.e6.	6.4	35
90	Development of a highâ€sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARSâ€CoVâ€2 spike glycoprotein in serum and saliva. Immunology, 2021, 164, 135-147.	4.4	35

#	Article	IF	Citations
91	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nature Communications, 2021, 12, 4817.	12.8	35
92	Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies. Biochemical Society Transactions, 2010, 38, 1349-1355.	3.4	34
93	Travellingâ€wave ion mobility and negative ion fragmentation of highâ€mannose <i>N</i>â€glycans. Journal of Mass Spectrometry, 2016, 51, 219-235.	1.6	34
94	Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry. ACS Chemical Biology, 2017, 12, 357-361.	3.4	34
95	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. Npj Vaccines, 2021, 6, 24.	6.0	33
96	Manipulation of cytokine secretion in human dendritic cells using glycopolymers with picomolar affinity for DC-SIGN. Chemical Science, 2017, 8, 6974-6980.	7.4	31
97	Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7031-7036.	7.1	31
98	Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding. Analytical Chemistry, 2018, 90, 7325-7331.	6.5	31
99	Ion Mobility Mass Spectrometry for Ion Recovery and Clean-Up of MS and MS/MS Spectra Obtained from Low Abundance Viral Samples. Journal of the American Society for Mass Spectrometry, 2015, 26, 1754-1767.	2.8	28
100	Travellingâ€wave ion mobility mass spectrometry and negative ion fragmentation of hybrid and complex <i>N</i>â€glycans. Journal of Mass Spectrometry, 2016, 51, 1064-1079.	1.6	28
101	Fragments of Bacterial Endoglycosidase S and Immunoglobulin G Reveal Subdomains of Each That Contribute to Deglycosylation. Journal of Biological Chemistry, 2014, 289, 13876-13889.	3.4	27
102	Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. Frontiers in Immunology, 2018, 9, 1116.	4.8	27
103	Principles of SARS-CoV-2 glycosylation. Current Opinion in Structural Biology, 2022, 75, 102402.	5.7	27
104	Structural Plasticity of the Semliki Forest Virus Glycome upon Interspecies Transmission. Journal of Proteome Research, 2014, 13, 1702-1712.	3.7	26
105	Collision Cross Sections and Ion Mobility Separation of Fragment Ions from Complex N-Glycans. Journal of the American Society for Mass Spectrometry, 2018, 29, 1250-1261.	2.8	26
106	Fragmentation of negative ions from N-linked carbohydrates: Part 6. Glycans containing oneN-acetylglucosamine in the core. Rapid Communications in Mass Spectrometry, 2014, 28, 2008-2018.	1.5	25
107	Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response. BMJ Open Respiratory Research, 2021, 8, e000872.	3.0	25
108	Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. Expert Review of Proteomics, 2017, 14, 881-890.	3.0	24

#	Article	IF	Citations
109	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Journal of Proteome Research, 2018, 17, 987-999.	3.7	23
110	A cross-neutralizing antibody between HIV-1 and influenza virus. PLoS Pathogens, 2021, 17, e1009407.	4.7	23
111	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	23
112	TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. Communications Biology, 2021, 4, 772.	4.4	23
113	Uukuniemi Phlebovirus Assembly and Secretion Leave a Functional Imprint on the Virion Glycome. Journal of Virology, 2014, 88, 10244-10251.	3.4	22
114	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. Journal of Molecular Biology, 2022, 434, 167332.	4.2	22
115	Isomer Information from Ion Mobility Separation of High-Mannose Glycan Fragments. Journal of the American Society for Mass Spectrometry, 2018, 29, 972-988.	2.8	21
116	Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein. Structure, 2022, 30, 1062-1074.e4.	3.3	21
117	The carbohydrate moiety of serum IgM from Atlantic cod (Gadus morhua L.). Fish and Shellfish Immunology, 2002, 12, 209-227.	3.6	19
118	Disruption of Î±-mannosidase processing induces non-canonical hybrid-type glycosylation. FEBS Letters, 2007, 581, 1963-1968.	2.8	18
119	A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding. Frontiers in Plant Science, 2020, 11, 609207.	3.6	18
120	Use of the Î±-mannosidase I inhibitor kifunensine allows the crystallization of apo CTLA-4 homodimer produced in long-term cultures of Chinese hamster ovary cells. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 785-789.	0.7	17
121	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Reports, 2022, 38, 110318.	6.4	17
122	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. Cardiovascular Research, 2022, 118, 3085-3096.	3.8	17
123	Antibodies expose multiple weaknesses in the glycan shield of HIV. Nature Structural and Molecular Biology, 2013, 20, 771-772.	8.2	16
124	Solution NMR Analyses of the C-type Carbohydrate Recognition Domain of DC-SIGNR Protein Reveal Different Binding Modes for HIV-derived Oligosaccharides and Smaller Glycan Fragments. Journal of Biological Chemistry, 2013, 288, 22745-22757.	3.4	16
125	Native functionality and therapeutic targeting of arenaviral glycoproteins. Current Opinion in Virology, 2016, 18, 70-75.	5.4	15
126	Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity. MAbs, 2016, 8, 1498-1511.	5.2	14

#	Article	IF	Citations
127	SARSâ€CoVâ€2â€specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multiâ€System Syndrome. Pediatric Allergy and Immunology, 2021, 32, 1125-1129.	2.6	13
128	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. PLoS Pathogens, 2021, 17, e1009807.	4.7	13
129	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of Virology, 2022, 96, JVI0155221.	3.4	13
130	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 27.	6.0	13
131	Analysis of variable N-glycosylation site occupancy in glycoproteins by liquid chromatography electrospray ionization mass spectrometry. Analytical Biochemistry, 2007, 361, 149-151.	2.4	12
132	Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. Biomolecules, 2015, 5, 2919-2934.	4.0	12
133	Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints. Analytical Chemistry, 2021, 93, 14392-14400.	6.5	12
134	SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation. Frontiers in Immunology, 0, 13, .	4.8	12
135	Identification of high-mannose and multiantennary complex-type N-linked glycans containing Î±-galactose epitopes from Nurse shark IgM heavy chain. Glycoconjugate Journal, 2009, 26, 1055-1064.	2.7	11
136	A monoclonal antibody with antiâ€Đâ€"like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. Transfusion, 2015, 55, 1501-1511.	1.6	11
137	Eliminating antibody polyreactivity through addition of <i>N</i>â€linked glycosylation. Protein Science, 2015, 24, 1019-1030.	7.6	11
138	Determination of N-linked Glycosylation in Viral Glycoproteins by Negative Ion Mass Spectrometry and Ion Mobility. Methods in Molecular Biology, 2015, 1331, 93-121.	0.9	11
139	Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy. Molecular Cancer Therapeutics, 2017, 16, 1887-1897.	4.1	11
140	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of Virology, 2020, 94, .	3.4	11
141	Therapeutic potential of deglycosylated antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10059-10060.	7.1	9
142	Site-Specific Glycosylation of Recombinant Viral Glycoproteins Produced in Nicotiana benthamiana. Frontiers in Plant Science, 2021, 12, 709344.	3.6	9
143	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood, 2021, 138, 1570-1582.	1.4	9
144	Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. Glycobiology, 2018, 28, 697-712.	2.5	8

#	Article	IF	Citations
145	Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2â€‰+â€‰breast carcinoma. Scientific Reports, 2022, 12, .	3.3	7
146	Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. MBio, 2021, 12, e0042921.	4.1	6
147	Harnessing post-translational modifications for next-generation HIV immunogens. Biochemical Society Transactions, 2018, 46, 691-698.	3.4	5
148	Glycan Remodeling with Processing Inhibitors and Lectin-Resistant Eukaryotic Cells. Methods in Molecular Biology, 2015, 1321, 307-322.	0.9	5
149	Augmenting glycosylationâ€directed folding pathways enhances the fidelity of HIV Env immunogen production in plants. Biotechnology and Bioengineering, 0, , .	3.3	5
150	Solutions to the Glycosylation Problem for Low- and High-Throughput Structural Glycoproteomics. , 2010, , 127-158.		4
151	Directing stem cell differentiation with antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17608-17609.	7.1	4
152	Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor. Molecular Immunology, 2015, 68, 234-243.	2.2	4
153	Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. Chemical Biology, 2017, , 300-357.	0.2	4
154	Antibody Glycosylation. , 2014, , 179-194.		2
155	Breaking the allergic response by disrupting antibody glycosylation. Journal of Experimental Medicine, 2015, 212, 433-433.	8.5	2
156	Immunoglobulin G Fc glycans are not essential for antibody-mediated immune suppression to murine erythrocytes. Blood, 2017, 130, 2902-2905.	1.4	2
157	Molecular Architecture of the SARS-CoV-2 Virus. SSRN Electronic Journal, 0, , .	0.4	2
158	Identification of N-glycans with GalNAc-containing antennae from recombinant HIV trimers by ion mobility and negative ion fragmentation. Analytical and Bioanalytical Chemistry, 2021, 413, 7229-7240.	3.7	1
159	Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets. Blood, 2019, 134, 1505-1505.	1.4	1
160	Structural Insights into Entry and Antibody Neutralization of Eastern Equine Encephalitis Virus. Biophysical Journal, 2019, 116, 576a.	0.5	0
161	Clinical significance of crown-like structures to trastuzumab response in patients with primary invasive HER2+ breast cancer.. Journal of Clinical Oncology, 2021, 39, e12533-e12533.	1.6	0
162	Formation and fragmentation of doubly and triply charged ions in the negative ion spectra of neutral N-glycans from viral and other glycoproteins. Analytical and Bioanalytical Chemistry, 2021, 413, 7277-7294.	3.7	0

#	Article	IF	Citations
163	Title is missing!. , 2020, 16, e1008665.		0
164	Title is missing!. , 2020, 16, e1008665.		0
165	Title is missing!. , 2020, 16, e1008665.		0
166	Title is missing!. , 2020, 16, e1008665.		0